Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Targeting TROP2 in drug-tolerant persister cells delays EGFR TKI resistance in NSCLC
PMID: 42314664 | Journal: Cancer Cell | Flag: 🟠 Novel Treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | TROP2 upregulation specifically in DTP cells as a TKI-resistance vulnerability is a mechanistically distinct and actionable insight. Prior work established DTP cells as drivers of resistance, but TROP2 as a DTP-specific therapeutic target is a meaningful advance. |
| Clinical Relevance | 7 | Directly addresses acquired TKI resistance — the dominant cause of NSCLC treatment failure. TROP2 ADCs (sacituzumab govitecan) are FDA-approved in other cancers, shortening the path to clinical testing. Capped at 7 because study is preclinical with abstract-only review. |
| Population Reach | 8 | EGFR-mutant NSCLC represents |
| Implementation Speed | 3 | Preclinical stage. Clinical combination trials are a logical next step, but regulatory approval of the combination is realistically 5–8+ years away. |
| Evidence Strength | 6 | Cancer Cell peer-reviewed, inferred multi-modal design (in vitro/in vivo/patient samples) consistent with journal standards. Abstract-only limits full assessment. Industry/FDA co-investigators add translational credibility. Non-human model cap applied partially (mixed species). |
Key quantitative result: Not explicitly reported in abstract; mechanistic endpoint is "delayed resistance emergence" — magnitude of delay not quantifiable from available data.
External validation: Not confirmed from available metadata; single study.
Main limitation: Preclinical-only (or predominantly preclinical) design; duration of resistance delay and clinical translatability of TROP2-DTP targeting unconfirmed. Abstract-only access.
Equity implications: EGFR-mutant NSCLC disproportionately affects East Asian populations and never-smokers including women; a successful combination strategy would benefit these currently underserved-by-alternatives groups. Access to TROP2 ADCs is currently limited by cost (~$20,000+/cycle).
Evidence Maturity: Exploratory ✓ (confirmed)
Article 2 — Spatially interpretable AI framework for neoadjuvant dual HER2 blockade in HER2+ breast cancer
PMID: 42315499 | Journal: Signal Transduction and Targeted Therapy | Flag: 🟠 Novel Treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Spatial AI for pCR prediction is emerging, but the interpretable spatial architecture applied specifically to dual HER2 blockade decision-making in a rigorous clinical cohort is a notable methodological step. Not entirely unprecedented in concept, but strong in execution tier. |
| Clinical Relevance | 8 | No validated predictive biomarker currently exists for neoadjuvant dual HER2 blockade selection. pCR is a surrogate for survival benefit. A validated AI tool here could prevent overtreatment toxicity and guide escalation/de-escalation decisions — directly actionable in existing workflows. |
| Population Reach | 6 | HER2+ breast cancer is |
| Implementation Speed | 5 | Retrospective validation exists; prospective integration into clinical pathology workflows requires multiplex imaging infrastructure (not universally available), but the treatment is already standardized, reducing regulatory friction for the biomarker. 3–5 year realistic horizon. |
| Evidence Strength | 6 | Retrospective validation design in a high-IF journal with stated clinical cohort. Abstract-only limits full assessment of validation cohort size, AUC, and external replication. Classified "Validated" by OpenClaw — I'd temper this to "Validated-Early" given retrospective design and no independent external cohort confirmed. |
Key quantitative result: Not reported in abstract; primary endpoint is pCR prediction accuracy — no AUC/sensitivity/specificity available from metadata.
External validation: Not confirmed from available metadata; single-institution cohort inferred.
Main limitation: Retrospective design; multiplex spatial pathology imaging infrastructure required (not universally available); no external prospective validation cohort confirmed; abstract-only.
Equity implications: Multiplex spatial imaging requires specialized pathology infrastructure concentrated in academic centers. Community hospitals and lower-income settings will face significant access barriers. Benefits initially concentrated in high-resource centers.
Evidence Maturity: Revised → Validated-Early (originally "Validated" — retrospective single-cohort AI validation; prospective confirmation needed before "Validated" designation is fully warranted)
Article 3 — Short-Term vs. Long-Term Efficacy of Endoscopic Sleeve Gastroplasty in 8880 Patients
PMID: 42315493 | Journal: Diabetes, Obesity & Metabolism | Flag: ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | ESG efficacy is an established literature; this is the largest meta-analysis but incremental rather than paradigm-shifting. Adds quantitative consolidation, not new mechanisms. |
| Clinical Relevance | 6 | Directly relevant to obesity management decision-making; positions ESG in the GLP-1 comparator landscape. Clinicians making referral decisions benefit from consolidated data. |
| Population Reach | 9 | Obesity affects ~1 billion people globally. ESG as a minimally invasive option addresses a massive undertreated population, particularly those ineligible for or resistant to pharmacotherapy. |
| Implementation Speed | 6 | ESG is already in clinical practice; this meta-analysis strengthens existing adoption. Immediately useful for guideline development and payer coverage arguments. |
| Evidence Strength | 7 | Systematic review and meta-analysis with n=8,880 is the strongest pooled evidence design available for this question. Heterogeneity across included studies is an inherent limitation (not quantifiable from abstract). |
Key quantitative result: n=8,880 pooled; specific %TBWL or %EWL not reported in available metadata.
External validation: Meta-analysis design inherently consolidates prior studies; no new primary cohort.
Main limitation: Meta-analytic heterogeneity across included studies; likely variable follow-up definitions for "long-term"; comparator arms unclear from abstract.
Equity implications: ESG is more accessible and lower-cost than bariatric surgery but still requires endoscopy infrastructure. GLP-1 pharmacotherapy has broader accessibility potential; ESG may particularly benefit those with GLP-1 contraindications or cost constraints.
Evidence Maturity: Validated ✓ (confirmed)
Article 4 — End-to-End PET/CT Interpretation with LLM-Orchestrated AI Agent
PMID: 42315314 | Journal: Journal of Nuclear Medicine | Flag: ⚪ Promising Preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | End-to-end agentic AI (LLM-orchestrated, not single-model) for a complex multi-step clinical imaging workflow is genuinely novel. Most AI diagnostics papers automate single subtasks; full pipeline orchestration is a qualitative leap. |
| Clinical Relevance | 5 | Pilot study with unconfirmed sample size; feasibility demonstrated but clinical accuracy vs. expert radiologists not yet benchmarked sufficiently. Relevant to nuclear medicine workforce shortages. |
| Population Reach | 6 | PET/CT is used across oncology, cardiology, and neurology. Workflow automation has broad reach, but impact is indirect (radiologist efficiency) rather than direct patient outcome change at this stage. |
| Implementation Speed | 4 | Requires LLM integration into hospital PACS/RIS infrastructure, regulatory clearance as a clinical AI tool, and validation at scale. 4–7 year realistic horizon. |
| Evidence Strength | 4 | Pilot study, small team, unconfirmed sample size, abstract-only. Feasibility demonstration — not a controlled accuracy trial. |
Key quantitative result: Not reported.
External validation: None confirmed; single-center pilot.
Main limitation: Unconfirmed sample size; no head-to-head accuracy comparison with radiologist standard; pilot feasibility only.
Equity implications: If validated, AI workflow automation could extend nuclear medicine diagnostic capacity to under-resourced settings with physician shortages. Conversely, LLM infrastructure costs may concentrate benefit in high-resource centers.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 5 — Trends and Disparities in CAR-T Therapy Utilization in the US (2017–2022)
PMID: 42315023 | Journal: Transplantation and Cellular Therapy | Flag: 🟡 Underserved Population
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Disparities in CAR-T access are a known concern; this is the most comprehensive US national database analysis to date but confirms rather than discovers a new phenomenon. |
| Clinical Relevance | 6 | Directly informs health policy, hospital credentialing decisions, and payer/advocacy strategies. Not a clinical treatment advance but actionable for system-level change. |
| Population Reach | 6 | CAR-T is currently approved for hematologic malignancies (~100,000+ eligible US patients/year across indications). Disparities affect racial minorities, rural, and low-income populations disproportionately. |
| Implementation Speed | 7 | Database study findings can immediately inform policy, advocacy, and reimbursement discussions. No regulatory hurdle; data are ready to use. |
| Evidence Strength | 6 | NIS (National Inpatient Sample) is the largest all-payer US inpatient database — high statistical power. Retrospective observational design with known limitations (coding accuracy, absence of clinical variables). |
Key quantitative result: Specific disparity magnitudes not available from abstract.
External validation: NIS is routinely used and validated for health services research.
Main limitation: NIS lacks clinical detail (disease stage, performance status, prior therapy lines); coding-based; does not capture outpatient CAR-T administration.
Equity implications: Central finding of the study — racial, socioeconomic, and geographic disparities are explicitly documented. This is a health equity–focused paper by design, flagging underserved Black, Hispanic, rural, and low-income populations.
Evidence Maturity: Validated ✓ (confirmed)
Article 6 — Clinical Validation of MC-80 Digital Morphology Analyzer
PMID: 42309506 | Journal: International Journal of Laboratory Hematology | Flag: 🟢 Near-Term Implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Digital morphology analyzers are an established product class; MC-80 validation is incremental. |
| Clinical Relevance | 6 | Directly relevant to hematology laboratory decision-making and procurement; reduces manual workload while maintaining diagnostic accuracy. |
| Population Reach | 7 | CBCs are among the most-ordered tests in medicine globally. Any validated automation tool affects routine care for a massive population indirectly. |
| Implementation Speed | 7 | Already-deployed technology class; clinical validation directly supports procurement and workflow adoption. Near-term implementable flag is well-justified. |
| Evidence Strength | 6 | Large-scale clinical validation design in the premier laboratory hematology journal. Sample size unconfirmed from abstract but described as "large-scale." |
Key quantitative result: Concordance with manual microscopy — specific kappa/correlation coefficients not available from abstract.
External validation: Comparison against manual expert microscopy is the standard validation approach; single-center or multi-center unclear.
Main limitation: Abstract-only; performance in abnormal/pathological differentials (blasts, atypical lymphocytes) particularly important and not detailed. Single-vendor analysis.
Equity implications: Automated digital morphology benefits resource-limited labs with insufficient trained morphologists — relevant to under-resourced hospital systems globally.
Evidence Maturity: Validated ✓ (confirmed)
Article 7 — Innate Immune Dysregulation in Multiple Myeloma
PMID: 42314557 | Journal: International Immunopharmacology | Flag: ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Comprehensive review, but innate immunity in MM is an active and populated field. |
| Clinical Relevance | 4 | Indirectly relevant — review does not present new clinical data but synthesizes mechanistic background useful for drug development. |
| Population Reach | 5 | Multiple myeloma ~35,000 new US cases/year; globally significant. |
| Implementation Speed | 2 | Basic science review; clinical translation requires drug development pipeline. |
| Evidence Strength | 3 | Narrative review — inherently lower evidence tier. |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 8 — Quantitative Molecular Cartography of Emergency Myelopoiesis
PMID: 42314682 | Journal: Cell Stem Cell | Flag: ⚪ Promising Preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Quantitative spatial/molecular cartography of emergency myelopoiesis at single-cell resolution is technically sophisticated and reveals conserved transcriptional architecture not previously mapped at this resolution. Strong basic science advance. |
| Clinical Relevance | 4 | Non-human primary model; clinical implications for AML/MDS are conceptual at this stage. Capped per non-human model rules. |
| Population Reach | 6 | AML/MDS together represent ~30,000+ US cases/year with poor prognosis; high unmet need amplifies the eventual reach of mechanistic breakthroughs. |
| Implementation Speed | 2 | Foundational basic science; translation requires target identification, drug development, and clinical testing — 10+ year horizon. |
| Evidence Strength | 5 | Cell Stem Cell publication standard with multiomics; abstract-only and mixed species limit score. Non-human cap applied. |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 9 — Liquid Biopsy-Guided Kidney-Sparing Management in UTUC
PMID: 42311269 | Journal: Frontiers in Oncology | Flag: ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | ctDNA in UTUC is an emerging but niche application; the organ-sparing framing is clinically relevant but this is a narrative review. |
| Clinical Relevance | 5 | Directly relevant to UTUC management decisions where kidney preservation has major quality-of-life implications. Framework-building but no new data. |
| Population Reach | 3 | UTUC is a rare malignancy (~7,000–8,000 US cases/year). Relative to unmet need, reach is moderate within the indication. |
| Implementation Speed | 4 | ctDNA platforms exist but clinical validation for UTUC-specific decisions is incomplete; review accelerates awareness but not deployment. |
| Evidence Strength | 3 | Narrative review; no primary data. |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 10 — AI-Enhanced RV Perfusion Quantification on PET/CT
PMID: 42315311 | Journal: Journal of Nuclear Medicine | Flag: ⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | RV perfusion quantification is a genuine gap; AI application to the "forgotten right ventricle" is a meaningful extension beyond established LV AI tools. |
| Clinical Relevance | 5 | Relevant to heart failure, pulmonary hypertension, and arrhythmia workup — but downstream clinical impact dependent on outcome validation studies. |
| Population Reach | 6 | RV dysfunction is common in heart failure and pulmonary hypertension (millions globally); improved quantification could have wide indirect impact. |
| Implementation Speed | 5 | Multicenter retrospective validation exists; integration into clinical PET/CT software is technically feasible but requires further prospective outcome validation. |
| Evidence Strength | 6 | Multicenter retrospective validation with 25-author multi-institutional team suggests reasonable dataset size. Abstract-only limits full assessment. |
Evidence Maturity: Validated ✓ (confirmed)
Article 11 — Barriers to Physical Activity in Middle-Aged and Older Adults with HIV
PMID: 42311983 | Journal: Frontiers in Public Health | Flag: 🟡 Underserved Population
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Stigma, fatigue, and side effects as barriers to physical activity in HIV+ populations are well-established; qualitative synthesis adds incremental value. |
| Clinical Relevance | 4 | Clinically useful for designing interventions but does not change acute care or treatment decisions. |
| Population Reach | 5 | ~38 million people living with HIV globally; aging HIV+ population is growing. Moderate reach for a public health intervention topic. |
| Implementation Speed | 5 | Qualitative findings can directly inform intervention design and clinician behavior; low-cost translation pathway. |
| Evidence Strength | 4 | Qualitative systematic review — appropriate methodology for the question but inherently lower evidence tier. |
Evidence Maturity: Exploratory ✓ (confirmed)
Article 12 — Cardiotoxicity Recommendations for Pediatric Acute Leukemia (SFCE)
PMID: 42315465 | Journal: Bulletin du Cancer | Flag: 🟢 Near-Term Implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Practice guideline codifying existing evidence; incremental update to current cardiotoxicity monitoring standards. |
| Clinical Relevance | 7 | Directly actionable for pediatric hematology-oncology centers. Standardizes cardiac monitoring thresholds for a population at significant long-term cardiovascular risk. |
| Population Reach | 5 | Pediatric acute leukemia ~3,000–4,000 US cases/year; broader global applicability. High impact within the population despite limited absolute numbers. Population Reach scored relative to the pediatric oncology population and unmet need. |
| Implementation Speed | 7 | Practice guideline — directly implementable in French pediatric oncology centers; adaptable internationally. |
| Evidence Strength | 6 | Practice Guideline from a national specialty committee; evidence synthesis methodology not detailed in abstract, but committee consensus + national endorsement provides reasonable credibility. |
Evidence Maturity: Validated ✓ (confirmed)
PHASE 3 — Ranking
Composite Impact Score Calculation
| # | Article | Clin Rel (30%) | Pop Reach (25%) | Sci Nov (20%) | Impl Speed (15%) | Evid Str (10%) | Composite | Triage Score |
|---|---|---|---|---|---|---|---|---|
| 1 | TROP2/DTP NSCLC (A1) | 7 | 8 | 8 | 3 | 6 | 6.80 | 8 |
| 2 | Spatial AI HER2+ BC (A2) | 8 | 6 | 7 | 5 | 6 | 6.90 | 8 |
| 3 | ESG Meta-Analysis (A3) | 6 | 9 | 4 | 6 | 7 | 6.60 | 7 |
| 4 | LLM PET/CT Agent (A4) | 5 | 6 | 8 | 4 | 4 | 5.55 | 7 |
| 5 | CAR-T Disparities (A5) | 6 | 6 | 4 | 7 | 6 | 5.85 | 6 |
| 6 | MC-80 Morphology (A6) | 6 | 7 | 4 | 7 | 6 | 6.00 | 6 |
| 7 | MM Innate Immunity (A7) | 4 | 5 | 4 | 2 | 3 | 3.80 | 5 |
| 8 | Emergency Myelopoiesis (A8) | 4 | 6 | 8 | 2 | 5 | 4.85 | 5 |
| 9 | UTUC Liquid Biopsy (A9) | 5 | 3 | 4 | 4 | 3 | 3.95 | 5 |
| 10 | RV Perfusion AI (A10) | 5 | 6 | 6 | 5 | 6 | 5.50 | 5 |
| 11 | HIV Physical Activity (A11) | 4 | 5 | 3 | 5 | 4 | 4.15 | 5 |
| 12 | Pediatric Leukemia Cardiotox (A12) | 7 | 5 | 3 | 7 | 6 | 5.75 | 5 |
Note: A4 (LLM PET/CT) has Evidence Strength 4/10 and therefore cannot rank #1 per ranking rules. A1 composite 6.80 is a tiebreaker call vs. A2 composite 6.90; A2 ranks #1 by composite score, with Evidence Strength tied (6) and Clinical Relevance favoring A2 (8 vs. 7).
⚠️ Conflicting Signals Note
No direct head-to-head conflicting findings exist across this batch. However, Articles 1 and 2 both address the challenge of treatment resistance/overtreatment in solid tumors from complementary angles (biological vs. predictive AI approaches). The batch does not contain contradictory data — the primary tension is one of evidence maturity: A1 offers a mechanistic biological answer in a preclinical model, while A2 offers a clinical prediction tool tested in a human retrospective cohort. These are complementary, not conflicting.
Final Ranked Table
| Rank | Article | Composite Score | Triage Score | Clin Rel | Pop Reach | Sci Nov | Impl Speed | Evid Str | Study Design | Priority Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Spatial AI for HER2+ BC neoadjuvant (A2) | 6.90 | 8 | 8 | 6 | 7 | 5 | 6 | Retrospective AI validation, human cohort | 🟠 Novel Treatment |
| 2 | TROP2/DTP NSCLC TKI resistance (A1) | 6.80 | 8 | 7 | 8 | 8 | 3 | 6 | Preclinical mechanistic + patient samples | 🟠 Novel Treatment |
| 3 | ESG meta-analysis, n=8,880 (A3) | 6.60 | 7 | 6 | 9 | 4 | 6 | 7 | Systematic review & meta-analysis | ⬜ Standard |
| 4 | MC-80 morphology analyzer (A6) | 6.00 | 6 | 6 | 7 | 4 | 7 | 6 | Large-scale clinical validation | 🟢 Near-Term Implementable |
| 5 | CAR-T disparities US 2017–2022 (A5) | 5.85 | 6 | 6 | 6 | 4 | 7 | 6 | Retrospective national database (NIS) | 🟡 Underserved Population |
| 6 | Pediatric leukemia cardiotoxicity guideline (A12) | 5.75 | 5 | 7 | 5 | 3 | 7 | 6 | Clinical practice guideline | 🟢 Near-Term Implementable |
| 7 | LLM-orchestrated PET/CT AI agent (A4) | 5.55 | 7 | 5 | 6 | 8 | 4 | 4 | Prospective pilot | ⚪ Promising Preliminary |
| 8 | RV perfusion AI PET/CT (A10) | 5.50 | 5 | 5 | 6 | 6 | 5 | 6 | Retrospective multicenter validation | ⬜ Standard |
| 9 | Emergency myelopoiesis cartography (A8) | 4.85 | 5 | 4 | 6 | 8 | 2 | 5 | Preclinical multiomics | ⚪ Promising Preliminary |
| 10 | HIV physical activity barriers (A11) | 4.15 | 5 | 4 | 5 | 3 | 5 | 4 | Qualitative systematic review | 🟡 Underserved Population |
| 11 | UTUC liquid biopsy review (A9) | 3.95 | 5 | 5 | 3 | 4 | 4 | 3 | Narrative review | ⬜ Standard |
| 12 | MM innate immunity review (A7) | 3.80 | 5 | 4 | 5 | 4 | 2 | 3 | Narrative review | ⬜ Standard |
Rank Justification Summaries
Rank 1 — Spatial AI for HER2+ Breast Cancer (A2): This Signal Transduction & Targeted Therapy paper addresses one of the most persistent clinical gaps in breast oncology: there is currently no validated biomarker to guide neoadjuvant dual HER2 blockade selection. A spatially interpretable AI framework operating on multiplex pathology tissue — published in a ~40 IF Nature Partner journal — achieves the highest Clinical Relevance score in the batch (8/10). The retrospective design limits Evidence Strength, and multiplex imaging infrastructure is a real-world barrier, but the direct clinical application to a high-prevalence, well-resourced disease with an existing treatment paradigm gives this the best near-term path to meaningful impact.
Why it matters: Every year, tens of thousands of HER2+ breast cancer patients receive neoadjuvant pertuzumab + trastuzumab without knowing in advance who will achieve a pathologic complete response. A validated AI tool that answers that question before treatment begins could spare non-responders from unnecessary toxicity and direct them to alternative regimens sooner.
Rank 2 — TROP2/DTP NSCLC (A1): Acquired resistance to EGFR TKIs is the defining clinical problem in the largest molecularly defined lung cancer subgroup, and this Cancer Cell paper offers a novel, pharmacologically tractable mechanism: TROP2 upregulation in drug-tolerant persister cells. The near-term clinical logic is compelling — TROP2 ADCs are already FDA-approved, making a combination trial feasible without de novo drug development. Scored #2 due to its preclinical stage (lower Implementation Speed) despite equal Triage Score.
Why it matters: Nearly every EGFR-mutant NSCLC patient will eventually develop resistance to their TKI. Identifying a druggable target before resistance fully establishes provides a rational window for combination intervention — potentially transforming TKI therapy from a finite treatment to a longer-term strategy.
Rank 3 — ESG Meta-Analysis, n=8,880 (A3): The largest pooled evidence base for endoscopic sleeve gastroplasty positions ESG in the GLP-1 era comparator landscape for obesity management. Population Reach is the highest in the batch (9/10) and Evidence Strength is the highest of any article (7/10 for a meta-analysis of this size). Ranked #3 due to lower Scientific Novelty — this is synthesis, not discovery.
Why it matters: With GLP-1 agonists dominating obesity treatment conversations, this meta-analysis provides the strongest available evidence base for where endoscopic procedures fit — essential data for clinicians, payers, and patients navigating an expanding treatment landscape.
Rank 4 — MC-80 Digital Morphology Analyzer (A6): Near-term implementable flag is fully warranted. Clinical validation of a digital morphology platform in the premier laboratory hematology journal directly supports lab procurement decisions with high Implementation Speed (7/10) and broad indirect Population Reach (7/10) given the ubiquity of CBC differential testing globally.
Rank 5 — CAR-T Disparities (A5): The first national-scale US evidence base documenting CAR-T access inequities across race, income, and geography. Not a treatment advance, but directly actionable for health policy and advocacy. High Implementation Speed because the findings require no regulatory pathway — they are ready to inform policy today.
Rank 6 — Pediatric Leukemia Cardiotoxicity Guideline (A12): Practice guidelines for a well-defined pediatric population with significant long-term cardiovascular risk. Clinical Relevance (7/10) and Implementation Speed (7/10) are strong; low Scientific Novelty and small absolute population size limit composite ranking. Immediately deployable within French (and adaptable to international) pediatric oncology centers.
Ranks 7–12: The remaining articles are valuable contributions to their respective fields but are either pilot/feasibility studies (A4), foundational basic science (A8), narrative reviews (A7, A9), or qualitative systematic reviews (A11) that carry lower Evidence Strength or Clinical Relevance scores that prevent higher placement under the weighted composite formula.